Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal [Yahoo! Finance]
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Yahoo! Finance
the firm's price target on Centessa to $38 from $35 with a Buy rating on the shares. Needham suggested that Centessa's stock momentum is poised to persist through 2026 due to the forthcoming data from the dose-escalation cohorts of the ongoing ORX-750 Phase 2a study. Consequently, the firm identified the company as one of the most compelling acquisition targets within the biotech sector for the coming year. Furthermore, on December 10, Oppenheimer assumed coverage of Centessa with an Outperform rating with a price target of $62, which was brought up from $40. The firm has been designated a top pick by Oppenheimer, largely due to its pipeline of potentially best-in-class orexin agonists. Oppenheimer anticipates a commercial launch in H1 2028, projecting that these treatments will dramatically broaden the narcolepsy market by improving diagnosis rates, patient uptake, compliance, and pricing power relative to existing therapies. Believing that the company is currently significantly un
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual MeetingGlobeNewswire
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis [Yahoo! Finance]Yahoo! Finance
CNTA
Earnings
- 8/12/25 - Miss
CNTA
Sec Filings
- 1/7/26 - Form 8-K/A
- 1/2/26 - Form 144
- 12/11/25 - Form 8-K
- CNTA's page on the SEC website